Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher – Should You Buy?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN)’s share price was up 7.9% during mid-day trading on Thursday . The company traded as high as $0.3075 and last traded at $0.2990. Approximately 930,493 shares traded hands during mid-day trading, an increase of 44% from the average daily volume of 646,236 shares. The stock had previously closed at $0.2772.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TVGN. Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital reduced their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, November 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tevogen Bio has an average rating of “Hold” and an average price target of $5.00.

Tevogen Bio Price Performance

The stock has a market capitalization of $59.41 million, a price-to-earnings ratio of -1.57 and a beta of -0.80. The stock has a 50-day moving average of $0.33 and a 200 day moving average of $0.58.

Hedge Funds Weigh In On Tevogen Bio

Large investors have recently bought and sold shares of the business. Deutsche Bank AG grew its holdings in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after acquiring an additional 130,738 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.